In this video, I will go over Novo Nordisk's (NVO-3.62%) and Eli Lilly's recent earnings report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

Choosing the best acoustic guitar for your personal needs is a tough one. With so many options on offer these days it’s not surprising that many find themselves faced with option paralysis when ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...